News for ImpediMed Limited (IPD.AX)

Global Revenue: Down 9% due to AstraZeneca clinical trial reviews no longer in progress.Core Business Revenue: Up 14% on FY23, primarily driven by the US marke

Revenue: $4.8 million for the half year, compared with $5.7 million in half 1 FY '23.SOZO Units Sold: 57 units, with 32 units sold in the U.S.Total Contracted

Aug 29, 2024 / 12:00AM GMTOperator Good morning, everybody, and welcome to the ImpediMed FY24 results presentation. With us this morning, we have Parmjot Bains,

Aug 28, 2024 / 12:00AM GMTOperator Thank you for standing by, and welcome to the ImpediMed Limited general meeting. I would now like to hand the conference over

Feb 27, 2024 / 12:00AM GMTOperator Thank you for standby, and welcome to the ImpediMed Limited Half Year Results Call. (Operator Instructions) I would now like

Feb 01, 2024 / 12:00AM GMTOperator Thank you for standing by, and welcome to the ImpediMed Limited 4C conference call. (Operator Instructions) I would now like

The ASX200 had a strong start to the week rising 0.86% to 7989.60 points – not far off the recently hit 8000 level.

Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.091% to 7,605.60.

The ASX200 ended up only .13 of a per cent, on a day when energy ran on OPEC plans to cut production and the Optus CEO resigned.

ImpediMed (ASX: IPD) has undergone significant leadership and board changes in a bid to maximize growth potential and streamline operations.

At the $240 million Perennial Better Future Trust, healthcare stocks are a critical component of our ESG-focused portfolio.

Telehealth, mental health and aged care stocks rallied on Wednesday following the Budget announcement which include billions for healthcare.

The US banking sector is in shambles as regional banks got crushed as expectations remain high that we will see more banking failures.

The ASX is expected to fall on Friday on further fears surrounding the global banking sector — US bank stocks continue to tumble, dragging Wall Street down.

The healthcare sector is ripe for disruption and artificial intelligence will play a big part in future drug discovery.

It's Thursday on Stockhead. The ASX200 closed down 0.08% on Wednesday and today's all about easing inflation and ASX gold.

While the goldies put on a +2.0% show, the rest of the market struggled today, leaving the benchmark down 0.08% on another wan Wednesday.

The ASX rallied from a -0.5% dip to hit lunch flat, CPI data hits market expectations while Brookfield's oil reserve looks better than ever.

Like Wall Street, local markets ended the week lower, but Japanese stocks look strong and the EU benchmark is at bold 14 month highs.